NEW YORK, NY / ACCESSWIRE / February 3, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
NBEVQ Shareholders Click Here: https://www.zlk.com/pslra-1/newage-class-action-submission-form?prid=36227&wire=1
EYE Shareholders Click Here: https://www.zlk.com/pslra-1/national-vision-class-action-submission-form?prid=36227&wire=1
IVVD Shareholders Click Here: https://www.zlk.com/pslra-1/invivyd-loss-submission-form?prid=36227&wire=1
* ADDITIONAL INFORMATION BELOW *
NewAge, Inc. (OTCMKT:NBEVQ)
NBEVQ Lawsuit on behalf of: investors who purchased January 18, 2018 - October 18, 2022
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/newage-class-action-submission-form?prid=36227&wire=1
According to the filed complaint, during the class period, NewAge, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company and defendants had no relationship with the military or FamilyMart; (2) the Company and defendants overstated the business agreements that they did have; (3) the Company and defendants never produced or sold a proprietary CBD beverage; (4) the Company lacked adequate internal controls; (5) as a result the Company had a heightened risk of regularly scrutiny and ultimately subject to an SEC investigation and action; and (6) as a result of the foregoing, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
National Vision Holdings, Inc. (NASDAQ:EYE)
This lawsuit is on behalf of all persons who purchased shares of National Vision common stock between May 13, 2021, and May 9, 2022, both dates inclusive.
Lead Plaintiff Deadline : March 28, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/national-vision-class-action-submission-form?prid=36227&wire=1
According to the filed complaint, (a) National Vision was experiencing extraordinary wage and labor pressures as a result of intense competition and disruptions in the labor market due to the COVID-19 pandemic; (b) National Vision had made a significant multi-million dollar investment in wage and compensation payments to its vision care professionals in order to prevent mass defections in the middle of 2021; (c) the enhanced payouts were expected to negatively impact the Company's fourth quarter 2021 costs and profit margins to an extent materially greater than what had been disclosed to investors; (d) as a result of (a)-(c) above, the Company's profitability metrics were expected to deteriorate below not only favorable 2020 results, but also pre-pandemic levels; e) the Company's recruitment and retention efforts had not been successful and there was a substantial undisclosed risk that National Vision would experience staff and optometrist shortages and capacity constraints.
Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ:IVVD)
This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.
Lead Plaintiff Deadline : April 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/invivyd-loss-submission-form?prid=36227&wire=1
According to the filed complaint, (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: https://www.accesswire.com/737992/CLASS-ACTION-UPDATE-for-NBEVQ-EYE-and-IVVD-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders